Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research.

Front Cardiovasc Med · 2023 · PMC9922727 · PMID 36793473

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For example, a retrospective analysis of spironolactone use in PAH patients in ARIES-1 and ARIES-2 trials showed a trend toward improved 6-min walking distance (6-MWD) and circulating B-type natriuretic peptide (BNP) levels with the combination of spironolactone and ambrisentan (ET-A antagonist) and compared to ambrisentan alone ( 22 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.